The study by Erol et al.3 that we cited in our Review reported 27 recurrent venous thrombotic events among 22 of 40 (55%) patients with Behçet syndrome. Of these 27 events, 15 (55.5%) occurred while patients were on immunosuppressants alone, 2 (7.4%) occurred on combined immunosuppressants and anticoagulation, and 2 (7.4%) occurred on anticoagulation alone. The recurrence rate was significantly lower in the group receiving the combination therapy than in the group receiving immunosuppressants only, suggestive of a potential benefit of combination therapy in selected cases.
Reply to 'Potential benefit of anticoagulation in Behçet syndrome' / Fagni, F., Bagni, G., Bello, F., Hill, C.L., Mohammad, A.J., Moiseev, S., Olivotto, I., Seyahi, E., Emmi, G.. - In: NATURE REVIEWS. RHEUMATOLOGY. - ISSN 1759-4804. - ELETTRONICO. - 21:(2025), pp. 755-755. [10.1038/s41584-025-01317-7]
Reply to 'Potential benefit of anticoagulation in Behçet syndrome'
Fagni, Filippo;Bagni, Giacomo;Bello, Federica;Olivotto, Iacopo;Emmi, Giacomo
2025
Abstract
The study by Erol et al.3 that we cited in our Review reported 27 recurrent venous thrombotic events among 22 of 40 (55%) patients with Behçet syndrome. Of these 27 events, 15 (55.5%) occurred while patients were on immunosuppressants alone, 2 (7.4%) occurred on combined immunosuppressants and anticoagulation, and 2 (7.4%) occurred on anticoagulation alone. The recurrence rate was significantly lower in the group receiving the combination therapy than in the group receiving immunosuppressants only, suggestive of a potential benefit of combination therapy in selected cases.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
